188 related articles for article (PubMed ID: 34958516)
1. Current treatment strategies and emerging therapies for cutaneous lymphoma.
Yonekura K
J Dermatol; 2022 Feb; 49(2):223-231. PubMed ID: 34958516
[TBL] [Abstract][Full Text] [Related]
2. Current and emerging treatment strategies for cutaneous T-cell lymphoma.
Lansigan F; Foss FM
Drugs; 2010 Feb; 70(3):273-86. PubMed ID: 20166766
[TBL] [Abstract][Full Text] [Related]
3. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
Duvic M
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):33-40. PubMed ID: 17474358
[TBL] [Abstract][Full Text] [Related]
4. Management of refractory early-stage cutaneous T-cell lymphoma.
Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
[TBL] [Abstract][Full Text] [Related]
5. Treatment of cutaneous T cell lymphoma: current status and future directions.
Apisarnthanarax N; Talpur R; Duvic M
Am J Clin Dermatol; 2002; 3(3):193-215. PubMed ID: 11978140
[TBL] [Abstract][Full Text] [Related]
6. Topical and systemic retinoid therapy for cutaneous T-cell lymphoma.
Kempf W; Kettelhack N; Duvic M; Burg G
Hematol Oncol Clin North Am; 2003 Dec; 17(6):1405-19. PubMed ID: 14710892
[TBL] [Abstract][Full Text] [Related]
7. Novel therapies for cutaneous T-cell lymphomas.
Horwitz SM
Clin Lymphoma Myeloma; 2008 Dec; 8 Suppl 5():S187-92. PubMed ID: 19073526
[TBL] [Abstract][Full Text] [Related]
8. CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model.
Wang Z; Ma J; Zhang H; Ramakrishna R; Mintzlaff D; Mathes DW; Pomfret EA; Lucia MS; Gao D; Haverkos BM; Wang Z
FEBS Open Bio; 2023 Jul; 13(7):1309-1319. PubMed ID: 37157185
[TBL] [Abstract][Full Text] [Related]
9. Systemic therapy of cutaneous T-cell lymphoma (CTCL).
Alpdogan O; Kartan S; Johnson W; Sokol K; Porcu P
Chin Clin Oncol; 2019 Feb; 8(1):10. PubMed ID: 30818958
[TBL] [Abstract][Full Text] [Related]
10. Choices in the treatment of cutaneous T-cell lymphoma.
Hymes KB
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):18-23. PubMed ID: 17474355
[TBL] [Abstract][Full Text] [Related]
11. Emerging drugs for the treatment of cutaneous T-cell lymphoma.
Cheng M; Zain J; Rosen ST; Querfeld C
Expert Opin Emerg Drugs; 2022 Mar; 27(1):45-54. PubMed ID: 35235473
[TBL] [Abstract][Full Text] [Related]
12. Integrating novel systemic therapies for the treatment of mycosis fungoides and Sézary syndrome.
Prince HM; Querfeld C
Best Pract Res Clin Haematol; 2018 Sep; 31(3):322-335. PubMed ID: 30213403
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease.
Argnani L; Broccoli A; Zinzani PL
Cancer Treat Rev; 2017 Dec; 61():61-69. PubMed ID: 29102679
[TBL] [Abstract][Full Text] [Related]
14. Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.
Van-de-Velde V; Zhou Y
J Cutan Med Surg; 2019; 23(3):319-327. PubMed ID: 30943788
[TBL] [Abstract][Full Text] [Related]
15. Future perspectives in the treatment of cutaneous T-cell lymphoma (CTCL).
Dummer R
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S33-6. PubMed ID: 16516674
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy.
Chung CG; Poligone B
Curr Hematol Malig Rep; 2015 Dec; 10(4):468-76. PubMed ID: 26626770
[TBL] [Abstract][Full Text] [Related]
17. Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome.
Photiou L; van der Weyden C; McCormack C; Miles Prince H
Curr Oncol Rep; 2018 Mar; 20(4):32. PubMed ID: 29572582
[TBL] [Abstract][Full Text] [Related]
18. Antibody-Based Therapies for Cutaneous T-Cell Lymphoma.
Welborn M; Duvic M
Am J Clin Dermatol; 2019 Feb; 20(1):115-122. PubMed ID: 30430444
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous T-cell lymphomas-An update 2021.
Kempf W; Mitteldorf C
Hematol Oncol; 2021 Jun; 39 Suppl 1():46-51. PubMed ID: 34105822
[TBL] [Abstract][Full Text] [Related]
20. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).
Duvic M; Kuzel TM; Olsen EA; Martin AG; Foss FM; Kim YH; Heald PW; Bacha P; Nichols J; Liepa A
Clin Lymphoma; 2002 Mar; 2(4):222-8. PubMed ID: 11970761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
